GlassScriptPhysician profile
Mary Beth Yackey
NPI 1386694461
$122,027.41
in general payments reported to CMS, 2019-2025
31 companies · $52K in 2025
The $52K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $69.47 · 2021: $662 · 2022: $585 · 2023: $28K · 2024: $40K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Consulting Fee: $36K · Travel and Lodging: $23K · Food and Beverage: $8,983 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,430 · Honoraria: $2,167 · Gift: $31.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,546.50 |
| Consulting Fee | $36,256.50 |
| Travel and Lodging | $22,521.45 |
| Food and Beverage | $8,983.18 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,430.00 |
| Honoraria | $2,166.50 |
| Gift | $31.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $75,643.20 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $23,059.72 | 2023-2025 | Syfovre |
| Notal Vision, INC. | $8,116.38 | 2019-2025 | Foresee Home |
| Topcon Healthcare, INC. | $5,431.79 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $2,333.80 | 2022-2025 | Xiidra, Miebo, Infuse |
| Tarsus Pharmaceuticals, INC. | $1,790.27 | 2024-2025 | Xdemvy |
| Haag-Streit USA, INC. | $1,294.38 | 2023-2024 | |
| Glaukos Corporation | $597.35 | 2023-2025 | Kxl System |
| Regeneron Healthcare Solutions, INC. | $533.16 | 2019-2025 | Eylea Hd, Eylea |
| Carl Zeiss Meditec USA, INC. | $490.96 | 2025 | Cirrus Hd-Oct |
| Alimera Sciences, INC. | $469.66 | 2019-2024 | Iluvien, Yutiq |
| Lkc Technologies, INC. | $450.00 | 2025 | |
| Alcon Vision LLC | $308.64 | 2022-2025 | Tryptyr, Hydrus Microstent |
| Coopervision INC. | $225.77 | 2023-2024 | Misight Contact Lens |
| Genentech USA, INC. | $160.64 | 2024-2025 | Vabysmo, Susvimo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $158.69 | 2024-2025 | Iluvien, Yutiq, Purified Cortrophin Gel |
| Aerie Pharmaceuticals, INC. | $146.62 | 2019 | |
| Astellas US LLC | $135.72 | 2024 | Izervay |
| Johnson & Johnson Vision Care, INC. | $126.71 | 2023 | Acuvue |
| Kala Pharmaceuticals, INC. | $122.06 | 2021 | |
| Astellas Pharma Global Development | $99.67 | 2025 | Izervay |
| Abbvie INC. | $62.16 | 2022-2025 | |
| Optos, INC. | $56.78 | 2019 | |
| Harrow Eye, LLC | $41.71 | 2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $40.73 | 2020-2021 | |
| Lombart Brothers, INC. | $36.23 | 2019 | |
| Dompe US, INC. | $22.76 | 2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $22.49 | 2024 | Acthar |
| Biogen, INC. | $19.54 | 2024 | Byooviz |
| Eyepoint US, INC. | $15.68 | 2022 | |
| Oyster Point Pharma, INC. | $14.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Yackey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.